Last reviewed 2026-04-23 · How we verify

Brivanib 400 mg, BID

Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.

Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation. Used for Hepatocellular carcinoma (Phase 2), Advanced solid tumors (Phase 2).

At a glance

Mechanism of action

Brivanib inhibits both FGFR and VEGFR signaling pathways, which are critical for tumor angiogenesis and growth. By blocking these receptor tyrosine kinases, the drug reduces new blood vessel formation to tumors and directly suppresses cancer cell proliferation. This dual-target approach aims to overcome resistance mechanisms that may develop with single-pathway inhibition.

Approved indications

• Hepatocellular carcinoma (Phase 2)
• Advanced solid tumors (Phase 2)

Common side effects

• Diarrhea
• Fatigue
• Nausea
• Hypertension
• Abdominal pain

Key clinical trials

• A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC (PHASE2)
• Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Brivanib 400 mg, BID CI brief — competitive landscape report
• Brivanib 400 mg, BID updates RSS · CI watch RSS
• Zai Lab (Shanghai) Co., Ltd. portfolio CI